Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of three drugs—bupivacaine, calcitonin, and fentanyl—used for analgesia. Bupivacaine is an amide-type local anesthetic that blocks voltage-gated sodium channels in neuronal membranes, inhibiting nerve impulse conduction and providing regional anesthesia or analgesia. Fentanyl is a potent synthetic opioid agonist primarily targeting the mu opioid receptor to produce strong analgesic effects by inhibiting pain signal transmission in the central nervous system. Calcitonin is a peptide hormone that inhibits osteoclastic bone resorption and has been explored for its potential analgesic properties, possibly through modulation of inflammatory mediators and direct action on central pain pathways. The combination aims to provide synergistic or additive pain relief by targeting different mechanisms involved in nociception and inflammation[1][2][6][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bupivacaine + calcitonin + fentanyl.